Skip to main content
. 2011 Mar 21;34(4):789–794. doi: 10.2337/dc11-0064

Table 1.

Phase 3 Cycloset efficacy trials

N Duration (months) Baseline HbA1c (%) Placebo-subtracted change in HbA1c (%) P
Monotherapy
159
6
8.7
−0.56
<0.02
Add-on to SU
494
6
9.4
−0.55
<0.0001
Add-on to various OHAs 3,095 12 8.3 −0.6 to −0.9 <0.01–0.001

SU, sulfonylurea.